The Oncology Podcast, brought to you by Oncology News Australia, is proud to present Episode 46 in our series The Oncology Journal Club.
This week Eva Segelov talks us through an early detection test using an independent validation set.
Craig Underhill looks at systematic barriers to participation in cancer treatment trials by Aboriginal and Torres Strait Islander cancer patients.
Hans Prenen is still MIA this episode but he’ll be back soon.
In the meantime, Eva also has a great selection of Quick Bites including a paper on COVID and burnout – which is a great moment to mention that in the coming weeks we’ll have a new series out on Mindful Leadership and strategies to address Burnout with Fran Boyle. So keep your ears out for that one!
Don’t miss this week’s Amazing Article of the Week… you’ll never look at a subway sandwich in the same way.
We wrap up with a fabulous interview with Belinda Kiley on cancer survival rates.
About The Oncology Journal Club:
We have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.
With The Oncology Podcast – and The Oncology Journal Club in particular – we are aiming to deliver oncology news differently,” Rachael Babin, Editor-in-Chief, Oncology News.
The Oncology Journal Club is hosted by Professor Eva Segelov, from Monash University. Eva is joined by Dr Craig Underhill from Albury-Wodonga and Professor Hans Prenen from Antwerp, Belgium. We hope you enjoy listening and find this a valuable and entertaining resource.
This Week’s Papers:
- Klein, E.A. et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Annals of Oncology, Access online here.
- Cunningham J, Garvey G. Are there systematic barriers to participation in cancer treatment trials by Aboriginal and Torres Strait Islander cancer patients in Australia? Aust N Z J Public Health. 2021 Feb;45(1):39-45. doi: 10.1111/1753-6405.13059. Epub 2020 Dec 21. PMID: 33347687. Access online here.
This Week’s Quick Bites:
- Tolaney SM. Et al. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol. 2021 Jun 2:JCO2003398. doi: 10.1200/JCO.20.03398. Epub ahead of print. PMID: 34077270. Access online here.
- Greer AC, et al. The impact of fertility preservation on the timing of breast cancer treatment, recurrence, and survival. Cancer. 2021 Jun 23. doi: 10.1002/cncr.33601. Epub ahead of print. PMID: 34161610. Access online here.
- Ogishi M, et al. Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. Nat Med. 2021 Jun 28. doi: 10.1038/s41591-021-01388-5. Epub ahead of print. PMID: 34183838. Access online here.
- Hlubocky FJet al. Occupational and Personal Consequences of the COVID-19 Pandemic on US Oncologist Burnout and Well-Being: A Study From the ASCO Clinician Well-Being Task Force. JCO Oncol Pract. 2021 Jul;17(7):e427-e438. doi: 10.1200/OP.21.00147. Epub 2021 Jun 21. PMID: 34152789. Access online here.
Amazing Paper of the Week:
Martinez, J. A Lab Analysis Was Done to Determine Whether a Subway Tuna Sandwich Contained Tuna DNA. Complex Media. Jun 22, 2021. Published online: Access online here.
Australians with a rare form of bowel cancer will have access to KEYTRUDA® (pembrolizumab) on the PBS from 1 August 2021. Access online here.
This Week’s Interview:
Link to the website: https://cancersurvivalrates.com/
- Kiely BE, et al. Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience. Support Care Cancer. 2013 Feb;21(2):369-76. doi: 10.1007/s00520-012-1526-4. Epub 2012 Jun 21. PMID: 22717918.Access online here.
- Vasista A, et al. Communicating prognostic information: what do oncologists think patients with incurable cancer should be told? Intern Med J. 2020 Dec;50(12):1492-1499. doi: 10.1111/imj.14739. PMID: 31904887.Access online here.
- Kiely BE, et al. The median informs the message: accuracy of individualized scenarios for survival time based on oncologists’ estimates. J Clin Oncol. 2013 Oct 1;31(28):3565-71. doi: 10.1200/JCO.2012.44.7821. Epub 2013 Sep 3. PMID: 24002504. Access online here.
Other Episodes Mentioned:
This Week’s Team:
Professor Eva Segelov
Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.
Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.
You can find Eva on Twitter here: @profevasegelov
Dr Craig Underhill
Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.
In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.
Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.
Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.
You can find Craig on Twitter here: @CraigUnderhill
Dr Belinda Kiely
Dr Belinda Kiely is a medical oncologist who sub-specialises in breast cancer. She is a Staff Specialist at Concord and Campbelltown hospitals in Sydney, Australia and a Senior Clinical Research Fellow and Oncology Prognostication Program Lead at the NHMRC Clinical Trials Centre, University of Sydney. Her research interests include breast cancer treatment, prognostication and survivorship. Dr Kiely led the development and evaluation of the iTool, a web-based tool to help oncologists explain survival time to patients with advanced cancer.
You can find Belinda on Twitter here: @BelindaKiely
Rachael Babin is Editor-in-Chief of The Oncology Newsletter, Publisher of Oncology News Host of The Oncology Podcast and Producer of The Oncology Journal Club. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.
With thanks to Craig Underhill, Gilberto Lopes, Mel Moore and Graham Knowles.
Connect with us on Twitter @OncologyNewsAus #OJC